Inhibition of glycolysis (32, 33), lipid synthesis (28, 36–38), and mTOR signaling (46–48) can control inflammation and alleviate disease activity in lupus mouse and SLE patients. This evidence concerns the gene MTOR and systemic lupus erythematosus.